REGENXBIO announced early completion of dosing in the confirmatory study of RGX-202, a gene therapy for Duchenne muscular dystrophy, due to strong patient demand. The company plans to submit a Biologics License Application (BLA) under the accelerated approval pathway in Q3 2026, aiming for FDA approval in the second half of 2027. RGX-202 showed promising safety and efficacy data, including significant microdystrophin expression and functional improvements in patients. REGENXBIO is preparing for commercial launch with in-house manufacturing capabilities.
Jyske Bank has publicly disclosed recent transactions made by its key managers in compliance with EU Market Abuse Regulation. These disclosures include trades by Peter Schleidt, Erik Gadeberg, and Lars Stensgaard Mørch dated June 24, 2026. Additional...
Jyske Bank has disclosed transactions made by its leading employees and their close associates in compliance with EU market abuse regulations. These disclosures coincide with the bank's ongoing share repurchase program, which started in February 2026...
Worldline, Crédit Agricole, and Mastercard have completed the first agentic payment transaction in France, marking a significant step in developing agentic commerce within a secure payment ecosystem. This transaction involved a Crédit Agricole client...
The Sanofi Foundation has announced a renewed focus on supporting children and young people, especially those with serious illnesses. It plans to invest €15 million annually in programs that improve early diagnosis, care, and social inclusion, partne...
Van Eck Associates Corporation notified a decrease in its voting rights in Endeavour Mining PLC to 6.947% as of June 19, 2026, down from a previous 7.995%. The reduction reflects changes in holdings across various Van Eck ETFs focused on gold miners ...
